Posted On: 01/25/2016 4:00:54 PM
Post# of 72447
Found this so far
"Enough data has been collected in the Phase 1 study for now advancing Kevetrin to a Phase 2 clinical trial. This data is being used to design the Kevetrin dosing regimen in the planned studies of patients with advanced ovarian carcinoma. An FDA meeting request had been submitted in the last week of October 2015. Subject to FDA guidance and authorization, t he Company plans a multi-arm study evaluating Kevetrin as a mono-therapy and as a component of a combination therapy. - See more at: http://cellceutix.com/cellceutix-files-form-1...GyuN6.dpuf
"Enough data has been collected in the Phase 1 study for now advancing Kevetrin to a Phase 2 clinical trial. This data is being used to design the Kevetrin dosing regimen in the planned studies of patients with advanced ovarian carcinoma. An FDA meeting request had been submitted in the last week of October 2015. Subject to FDA guidance and authorization, t he Company plans a multi-arm study evaluating Kevetrin as a mono-therapy and as a component of a combination therapy. - See more at: http://cellceutix.com/cellceutix-files-form-1...GyuN6.dpuf
(0)
(0)
